Tisch MS News

Multiple Sclerosis Journal has selected the recent Tisch MS publication "Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis," co-authored by Violaine Harris, PhD, and Saud Sadiq, MD, among others, as its cover article for October 2013.
Ricki Lewis, Ph.D., filed a report for the Multiple Sclerosis Discovery Forum on FDA approval for the upcoming clinical trial of MSC-NPs at the Tisch MS Research Center of New York. Lewis quotes multiple outside experts alongside Saud Sadiq, M.D., director of Tisch MS, on the science behind the trial and on the outstanding questions regarding MSC-NPs and MSC-NP therapy still unresolved in current research.
The stem cell research division of the Tisch MS Research Center of New York proudly announces Food and Drug Administration (FDA) approval of autologous, mesenchymal stem cell-derived neural progenitor cells (MSC-NPs) as an Investigational New Drug (IND) for an open label, phase I clinical trial in the treatment of multiple sclerosis.
A Research team lead by Violaine Harris, Ph.D., at the Tisch MS Research Center of New York, has just published findings on a new method of measuring disease activity in patients with multiple sclerosis (MS) (Harris, et al, Cerebrospinal fluid fetuin-A is a biomarker of active multiple sclerosis, Multiple Sclerosis Journal, Epub: 2/25/2013 doi: 10.1177/1352458513477923 ahead of print).  This important biomarker discovery is based on spinal fluid measurement of Fetuin
Tisch MS Research Center of New York has formally submitted a response to the Food and Drug Administration’s (FDA) clinical hold on our proposed Phase I trial of Mesenchymal Stem Cell-Derived Neural Progenitors in the treatment of multiple sclerosis. Per agency rules, this submission necessitates a reply from the FDA within 30 days of filing. Within another 30 days of the FDA’s reply, we expect to schedule a meeting in order to discuss the FDA’s comments on our submission.
Violaine Harris (Tisch MSRCNY) presented the following article in Journal Club. Article Title: A channelopathy contributes to cerebellar dysfunction in a model of multiple sclerosis Reference: S.D. Shields, PhD, X. Cheng, PhD, A. Gasser, PhD, C.Y. Saab, PhD, L. Tyrrell, MS, E.M. Eastman, BS, M. Iwata, PhD, P.J. Zwinger, BS, J.A. Black, PhD, S.D. Dib-Hajj, PhD, and Stephen G. Waxman, MD, PhD. (2012) Ann. Neurol. 71(2): 186-94
Tamara Vyshkina (Tisch MSRCNY) presented the following article in Journal Club. Article Title: Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis Reference: M.A. Rocca, MD, P. Valsasina, MSc, V. Martinelli, MD, P. Misci, MSc, A. Falini, MD, G. Comi, MD, and M. Filippi, MD. (2012) J. Neurology. 79 (Oct. 2): 1449-1457.
On Wednesday, June 12, 2013, Dr. Saud A. Sadiq and Dr. Violaine Harris met with a congressional supporter of our stem cell program. Following this discussion, The Tisch MS Research Center of New York submitted additional information to the FDA on June 18, 2013 and requested a formal meeting with the agency in the next 30 days.  We will keep you informed on the progress through an update on this website in approximately 6 weeks. 
Check out an interview with Dr. Sadiq, titled "Stem Cells Hold Potential to Repair Immune Responses in MS Patients" featured on Science World Report.
Congratulations to Dr. Sadiq for his neurology listing in New York Magazine’s 2013 Best Doctor’s Issue! This is a great achievement and acknowledgement of the hard work and dedication that happens on a daily basis at the IMSMP and Tisch MS Research Center of New York!

Pages

Subscribe to MSRCNY News